Amgen's Phase 3 wins are real, but at $466 the stock is already paying for them. Shares up 42% YTD and the most-followed narrative pegs fair value at $360, so the swing factor is MariTide manufacturin

What happened: Amgen ($AMGN) drew attention after positive Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis, with analysts lifting near term earnings expectations. Key numbers: Shares up 10.56% over the past month and 42.23% year to date. One year total shareholder return of 60.49%. Last close $466.01. Why it matters: The content frames a tension between the strong run and valuation, with the popular narrative citing manufacturing capacity limits while the DCF model points to undervaluation. Market: +1.1% today ($466.01), +44.3% YTD, 1.2x vol — as of 23:45 UTC Verified: Q3_2026 (Nov 3) revenue $9.7B vs $9.7B est; next print ~Feb 2

Amgen ($AMGN) drew attention after positive Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis, with analysts lifting near term earnings expectations.

The content frames a tension between the strong run and valuation, with the popular narrative citing manufacturing capacity limits while the DCF model points to undervaluation. Market: +1.1% today ($466.01), +44.3% YTD, 1.2x vol — as of 23:45 UTC Verified: Q3_2026 (Nov 3) revenue $9.7B vs $9.7B est; next print ~Feb 2